Portolan Capital Management’s DexCom DXCM Stock Holding History

Portolan Capital Management’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-31,169	Closed	-$2.72M	–	130
2025 Q2	$2.72M	Buy	+31,169	New	+$2.44M	0.17%	109

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Portolan Capital Management's DXCM Position: Q3 2025 in Review

Portolan Capital Management sold out of DexCom (DXCM) in Q3 2025, closing a stake of 31,169 shares — an estimated $2.72M sold.

Portolan Capital Management first reported a position in DXCM in Q2 2025 and held it in 1 quarter. The position peaked at $2.72M in Q2 2025. 911 funds tracked by Wall St. Rank hold DXCM as of Q3 2025.

Portolan Capital Management reported no remaining DexCom position as of Q3 2025 after selling out during the quarter.
Portolan Capital Management sold 31,169 DexCom shares in Q3 2025, an estimated $2.72M.
Portolan Capital Management first reported a position in DexCom in Q2 2025 and held it in 1 quarter.
Portolan Capital Management's DexCom position peaked at $2.72M in Q2 2025.
911 funds tracked by Wall St. Rank held DexCom as of Q3 2025.

Based on Portolan Capital Management's 13F filing for Q3 2025, filed 13 Nov 2025.